| Programme | |
|---|---|
| Welcome Remarks by the Conference Chairman | |
| Opening Symposium: Overview of HBV Functional Cure Moderators: Prof. Lim Seng Gee View Bio |
|
| Opening Lecture: Are we winning the battle against CHB? Prevention vs treatment – Prof. Geoffrey Dusheiko, UK View Bio |
|
| ICE-HBV strategy for functional cure – Prof. John Tavis, USA View Bio |
|
| Virologal Insights into functional cure Moderators: Prof. Peter Revill View Bio and Prof. John Tavis |
|
| Overview of virology of HBV and targets for therapy – Prof. John Tavis, USA View Bio |
|
| HBsAg loss: cccDNA silencing, loss or both? – Prof. Massimo Levrero, France View Bio |
|
| Directly Targeting cccDNA: are we there yet? (recording) – Prof. Fabien Zoulim, France View Bio |
|
| HBV Viral Integration : Implications for a HBV Cure – Dr. Thomas Tu, Australia View Bio |
|
| Free Paper: Long-read DNA sequencing reveals large reduction in HBV integration burden in HBsAg-negative patients – Dr. Cameron Soulette, Gilead Sciences Inc View Bio |
|
| Free paper: Illuminating the Live-Cell Dynamics of Hepatitis B Virus covalent closed circular DNA using CRISPR-Tag – Dr. Xiaonan, Zhang, University of Canberra, Australia |
|
| Lunch | |
| Immunological insights into functional cure Chair and Moderator: Prof. Markus Cornberg and Prof. Jonathan Karn |
|
| Interrogating the intrahepatic microenvironment using FNA – Dr. Loey Mak, Hong Kong View Bio |
|
| The liver transcriptome and HBV functional cure (recording) – Dr. Ram DasGupta, Singapore View Bio |
|
| Can innate immune mechanisms lead to HBV cure: lessons from HIV – Prof. Jonathan Karn, USA View Bio |
|
| Free Paper: Decreased intrahepatic NK exhaustion and increased activation with decreasing HBsAg levels in CHB patients – Dr. Sriram Narayanan View Bio |
|
| Strategies to reduce viral replication Chair and Moderator: Prof. Geoff Dusheiko and Dr. Loey Mak |
|
| Capsid inhibitors: where are they in the combination for HBV cure? – Prof. Man Fung Yuen, Hong Kong View Bio |
|
| Nucleoside analogues: are the necessary for functional cure? – Prof. Henry Chan, Hong Kong View Bio |
|
| Invited Oral & Free Paper Presentations | |
| Invited Presentation: Development of a Highly Potent Next Generation Core Inhibitor for the Treatment of Chronic Hepatitis B Infection (Recording) – Dr. Katie Kitrinos, Assembly Biosciences Inc View Bio |
|
| Free paper: Comparison of hepatitis B reactivation in patients with resolved hepatitis B infection receiving rituximab or non-rituximab based immunosuppressive therapy: does the presence of anti-HBs antibody reduce the risk of reactivation? – Dr. Valerie Shu Xian Yeap, Singapore |
|
| Invited Presentation: ASC22 (Envafolimab) a First-in-Class subcutaneously administered Antibody for HBV functional cure: Learnings from pre-clinical and clinical studies – Dr Jinzi Wu, Acletis Pharma Inc. |
|
| Tea Break | |
| Viewpoint Chair and Moderator: Prof. Ed Gane and Prof. Pietro Lampertico |
|
| Achieving functional cure without immunotherapy – Prof. Pei-Jer Chen View Bio |
|
| A roadmap for Biomarkers for HBV functional cure – Prof. Peter Revill, Australia View Bio |
|
| Invited Oral & Free Paper Presentations | |
| Invited Presentation: HBsAg Next Qualitative assay on-therapy reactivity predicts HBsAg rebound 24-weeks after therapy discontinuation – Dr. Mark Anderson, Abbott Diagnostics View Bio |
|
| Free paper: Deep Serum Proteome Profiling Revealed Novel Prognostic Markers for HBsAg Loss – Dr Zi Jie Lim, Singapore |
|
| Invited presentation: Exploratory Biomarkers for HBV – insights gained and future directions – Dr. Gavin Cloherty, Abbott Diagnostics View Bio |
|
| Closing remarks | |
The Science of HBV Cure Meeting 2023 Scientific Programme
June, 2023
2
June, 2023
3
| Programme | |
|---|---|
| Special Lecture Chair and Moderator: Prof. Peter Revill and Prof Pei Jer Chen |
|
| Absolute cure : a dream coming closer? – Prof. Fabien Zoulim View Bio |
|
| Reducing viral antigens Chair and Moderator: Prof. Peter Revill and Prof Pei Jer Chen |
|
| Anti-sense RNA strategies: ASO versus siRNA – Prof. Man Fung Yuen View Bio |
|
| Removing viral antigens using monoclonal antibodies – Prof. Ed Gane View Bio |
|
| Invited Presentation: The role of NAPs in HBV Functional Cure – Dr. Andrew Valliant, Replicor Inc View Bio, |
|
| Tea Break | |
| Invited Oral & Free Paper Presentations Chair and Moderator: Prof. Peter Revill and Prof. Pei Jer Chen |
|
| Invited Presentation: Phase 1 data on Roche Assets in HBV – Dr. Klaus Kuhlbusch, Roche View Bio |
|
| Free Paper: Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus (HBV) infection: changes in HBV DNA in patients not on stable nucleos(t)ide analogue therapy – Prof. Man Fung Yuen View Bio |
|
| Invited Presentation: The Development of VIR-2218 and VIR-3434 for the Treatment of chronic HBV Infection – Dr. Carey Hwang, Vir Biotechnology, Inc View Bio |
|
| Invited presentation: Update on AB-729, an RNAi therapeutic in Phase 2 development as a key component of a functional cure strategy for cHBV (Recording) – Dr Karen Sims, Arbutus Biopharma Corporation |
|
| Q&A | |
| Novel Therapies Chair and Moderator: Prof. Geoff Dusheiko & Dr. Thomas Tu |
|
| Novel agents and novel mechanisms – Prof. Ed Gane View Bio |
|
| Free paper: First demonstration of CRISPR-CAS13B-mediated suppression of Hepatitis B Virus replication and Protein Expression – Pre-Clinical investigations of a new therapeutic approach – Ms Laura McCoullough, Australia |
|
| Q&A | |
| Lunch | |
| Delta Cure: Chair and Moderator: Prof. Massimo Levrero |
|
| What is Delta cure and how to achieve it? – Prof. Pietro Lampertico View Bio |
|
| Immunology Forum Chair and Moderator: Prof. Ed Gane and Prof. Antonio Bertoletti |
|
| Adaptive immune recovery in patients with low qHBsAg – Prof. Markus Cornberg View Bio, Germany |
|
| Landscape of immune based therapies for functional cure – Prof. Antonio Bertoletti View Bio |
|
| Can combination immunotherapy lead to improved functional cure – Prof. Markus Cornberg View Bio |
|
| Invited Presentation: A Novel Arenavirus-Vectored Therapeutic Vaccine for HBV Cure. – Dr. Scott Balsitis, Gilead Sciences Inc View Bio |
|
| Invited Presentation: How will HBV Cures get to patients? The varied challenges of access to medicines in the 21st century – Ms Cammy Yuen, GlaxoSmithKline |
|
| Q&A | |
| Tea Break | |
| Combination Therapy Forum 1 Chair and Moderator: Prof. Pietro Lampertico |
|
| When should we start immunotherapy? De novo combination or sequential? – Prof. Geoff Dusheiko, Prof. Markus Cornberg, Prof. Antonio Bertoletti, Prof. Ed Gane, Dr. Carey Hwang, Prof. Jonathan Karn |
|
| Combination Therapy Forum 2 Chair and Moderator: Prof. Lim Seng Gee |
|
| Should siRNA or ASO be the backbone for combination therapy in functional cure? – Prof. Peter Revill, Prof. Yuen Man Fung, Prof. Massimo Levrero, Prof. John Tavis, Prof. Henry Chan, Dr. Dickens Theodore, Dr. Klaus Kuhlbusch |
|
| Closing remarks from Chairman | |